De-identified Health Data Market Trends, Size, Share & Analysis 2031

De-identified Health Data Market Size and Trends

De-identified health data market is estimated to be valued at USD 7.51 Bn in 2024 and is expected to reach USD 13.80 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 9.1% from 2024 to 2031. With increasing focus on data privacy and availability of large amounts of healthcare data, de-identified health data market is expected to witness rapid growth in the near future.

De-identified Health Data Market Key Factors

Discover market dynamics shaping the industry: Request sample copy

Rising demand for real-world evidence and integration of analytics in healthcare are also driving the market growth. Furthermore, increasing investments by pharmaceutical and medical devices companies in digital healthcare will boost the need for anonymized healthcare databases.

De-identified Health Data Market By Type of data

Discover high revenue pocket segments and roadmap to it: Request sample copy

Insights By Type of Data - Increased adoption of EHR drives clinical data segment growth

In terms of type of data, clinical data segment is estimated to contribute the highest market share of 20.1% in 2024, due to the widespread adoption of electronic health records (EHRs). EHRs store comprehensive patient information including medical history, diagnoses, treatments, and test results, all of which can be anonymized for secondary uses like research. Rising focus on value-based care encourages the use of big data analytics on clinical records to enhance patient outcomes, further boosting demand for de-identified clinical data in the healthcare sector.

Insights By Application- Industry push for real world evidence drives clinical research and trials segment growth

In terms of application, clinical research and trials segment is estimated to contribute the highest market share of 25.12% in 2024. The segment growth is driven by need for real-world evidence (RWE) to support regulatory requirements for long-term therapy effectiveness and safety. Leveraging de-identified healthcare databases enables cost-efficient, time-saving RWE generation through observational studies and post-marketing research.

Insights By End User- Pharmaceutical sector leads through the usage of extensive datasets

Pharmaceutical companies lead the de-identified health data market, holding an estimated 35.12% share of the market in 2024, by utilizing extensive datasets to advance drug development and personalized medicine. Other prominent segments—such as biotech firms, healthcare providers, insurers, research institutions, and government agencies—also leverage this data to gain insights into patient outcomes, population health, and risk management.

Regional Insights

De-identified Health Data Market Regional Insights

To learn more about this report, Request sample copy

Dominating Region- North America

North America holds a 39.2% share in the de-identified health data market in 2024, driven by advanced healthcare infrastructure, widespread EHR adoption, and supportive privacy regulations like HIPAA (Health Insurance Portability and Accountability Act). The presence of major pharmaceutical companies utilizing de-identified data for drug development, along with significant government and research funding, further strengthens North America’s market leadership.

Fastest-Growing Region- Asia Pacific

Asia Pacific is experiencing rapid growth in the de-identified health data market due to increasing healthcare spending, focus on improving patient outcomes, and growing adoption of advanced technologies. Key countries like China and India are leading the way with investments in healthcare infrastructure, digital health solutions, and AI technologies, driving innovation and expanding access to healthcare services, thus, driving the market growth.

De-identified Health Data Market Outlook for Key Countries

U.S. Dominance in De-Identified Health Data Market Due to its Advanced Healthcare Infrastructure

The U.S. leads the De-identified Health Data Industry due to its advanced healthcare infrastructure, widespread adoption of electronic health records (EHRs), and robust regulatory framework promoting data privacy. For instance, in June 2022, Truveta and Pfizer announced a strategic collaboration to continuously deliver safety insights using real-world, de-identified U.S. health data. Truveta's platform provides Pfizer with up-to-date data to identify, monitor, and evaluate potential signals in near-real time, supporting risk mitigation and further research efforts.

Examining Privacy Implications in Canada’s Virtual Healthcare Landscape

Canada's De-identified Health Data industry is growing due to increasing adoption of digital health platforms. For instance, in September 2022, CCLA, Canadian Civil Liberties Association, launched a report titled Virtual Healthcare Services in Canada: Digital Trails, De-Identified Data and Privacy Implications, led by Dr. Sheryl Spithoff. The study explores privacy concerns within Canada's growing virtual healthcare industry, focusing on data collection, sharing, and the implications of de-identified health information. It examines the potential risks of commercial data use, with privacy policies.

India's Rapid Growth in Digital Health Driven by Strategic Collaborations

India’s de-identified health data industry is growing rapidly due to strategic partnerships. For instance, on November 05, 2024, Monash University and Apollo Hospitals partnered to advance digital health research through data and technology sharing. The partnership grants Monash IT access to Apollo’s de-identified health data from over 200 million patients, enabling AI-driven research to enhance diagnoses and treatments for conditions like cancer, heart disease, and diabetes. This initiative aims to accelerate innovation in healthcare and improve patient outcomes across both India and Australia.

Accelerating Market Growth through Government Initiatives and Technological Advancements in China

China's de-identified health data industry is growing rapidly due to government initiatives like the "Healthy China 2030" plan, which integrates digital health technologies and data analytics into the healthcare system. In July 2023, China’s National Health Commission introduced a policy to encourage the use of de-identified health data for medical research and public health improvement. This initiative promotes collaboration between the private and public sectors, using data analytics to address key health challenges and advance healthcare solutions.

Digital Transformation Enhancing Healthcare Integration in Indonesia

Indonesia is driving de-identified health data sector through new product launches. For instance, in August 2022, Indonesia's Health Ministry launched SATUSEHAT platform, as part of its digital health transformation. It connects over 8,000 health facilities, streamlining patient records and enabling efficient data exchange. The platform integrates with health apps for easy access to medical histories, reducing the need for physical records. This initiative enhances Indonesia’s healthcare system by fostering innovation and improving health data integration across the country.

Market Concentration and Competitive Landscape

De-identified Health Data Market Concentration By Players

Get actionable strategies to beat competition: Request sample copy

Top Strategies Followed by De-identified Health Data Market Players

Established players in the global de-identified health data industry emphasize research and development to maintain a competitive edge. For example, in May 2020, IBM announced plans to invest over USD 6 billion annually to advance artificial intelligence and cloud technologies, enabling organizations to extract valuable insights from health data. IBM also forms strategic partnerships in areas like telehealth and genomics, enhancing its capability to offer comprehensive data-driven healthcare solutions.
Mid-sized companies focus on niche specialization and cost-effective offerings, targeting specific therapeutic areas or regional health systems with tailored products and services priced affordably to meet localized needs.
Small startups adopt a grassroots approach, often concentrating on specific segments within the de-identified data space. Some startups develop innovative methods to analyze socioeconomic data, while others focus on extracting insights from medical imagery. By addressing these narrow needs, they gain specialized expertise and create unique solutions.

Emerging Startups in the De-identified Health Data Market

Emerging startups in the de-identified health data industry are leveraging advanced technologies to enhance patient privacy while enabling data sharing for research and analytics. For instance, Orion Health announced advancements in its end-to-end de-identification software in January 2023, ensuring compliance with regulations like HIPAA and focusing on both structured and unstructured data.
Shaip detailed its automated solutions for anonymizing sensitive health information in March 2023. Skyflow uses techniques such as tokenization and polymorphic encryption to safeguard patient data, with significant discussions about its innovations occurring throughout 2023, particularly emphasized in February 2023. These developments highlight the dynamic nature of the de-identified health data sector and its commitment to privacy and security.

De-identified Health Data Industry News

In February 2024, Veradigm, a healthcare technology company, released its inaugural Veradigm Insights Report: Cardiovascular Conditions in 2024, which analyzes de-identified real-world data from 53 million cardiovascular patients. The report explores the prevalence of cardiovascular disease (CVD) and related conditions across U.S. states, including demographic insights by age, ethnicity, and sex.
In April 2023, Philips, a global health technology company, and MIT's Institute for Medical Engineering and Science (IMES) expanded their collaboration to provide a new, enhanced critical care data set for healthcare researchers. The updated eICU Collaborative Research Database (eICU-CRD) now includes de-identified data from 200,000 critical care patients, including COVID-19 cases, collected from over 200 hospitals. This broader dataset aims to advance machine learning and AI in healthcare by offering detailed clinical data such as vital signs, lab results, diagnoses, and treatment information.
In July 2021, Verana Health and Komodo Health, healthcare technology companies, partnered to integrate Komodo’s Healthcare Map with Verana’s de-identified EHR datasets, covering over 325 million patient journeys. This partnership offers life sciences researchers detailed patient pathway insights, encompassing treatment histories, hospitalizations, and socioeconomic factors. By merging clinical outcomes with real-world patient data, this partnership aims to advance research in ophthalmology, neurology, and urology to inform treatment development.

Key Takeaways from Analyst

De-identified health data industry growth is driven by increased demand from pharmaceutical and healthcare companies for personalized medicine and advanced analytics. While North America leads the market, Asia Pacific is poised for faster growth due to government support for advanced healthcare systems. Challenges include regulatory uncertainties, privacy concerns, and the risk of re-identification. Innovations in privacy-enhancing technologies and monetizing real-world data offer growth opportunities, but achieving standardized, high-quality datasets remains a key hurdle.

Market Report Scope

De-identified Health Data Market Report Coverage

Report Coverage	Details
Base Year:	2023	Market Size in 2024:	US$ 7.51 Bn
Historical Data for:	2019 to 2023	Forecast Period:	2024 to 2031
Forecast Period 2024 to 2031 CAGR:	9.1%	2031 Value Projection:	US$ 13.80 Bn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Type of Data: Clinical Data, Genomic Data, Patient Demographics, Prescription Data, Claims Data, Behavioral Data, Wearable and Sensor Data, Survey and Patient-Reported Data, Imaging Data , Laboratory Data, Social Determinants of Health (SDOH) Data, and Others By Application: Clinical Research and Trials, Public Health, Precision Medicine, Health Economics and Outcomes Research (HEOR), Population Health Management, Drug Discovery and Development, Healthcare Quality Improvement, Insurance Underwriting and Risk Assessment, and Others By End User: Pharmaceutical Companies, Biotechnology Firms, Healthcare Providers, Insurance Companies/Healthcare Payers, Research Institutions, Government Agencies, and Others
Companies covered:	IQVIA, Oracle (Cerner Corporation), Merative (Truven Health Analytics), Optum, Inc., BioTelemetry, Inc., Flatiron Health, Veradigm LLC, Medidata Solutions, Evidation Health, Inc., Komodo Health, Inc., Sundown Solutions, LLC, Clarify Health Solutions, Akrivia Health, Satori Cyber Ltd., Tempus, nference, Ciox Health, HealthVerity, Zebra Medical Vision, and Huma Therapeutics
Growth Drivers:	Increasing integration of data analytics in healthcare Growing regulatory frameworks supporting the use of de-identified data
Restraints & Challenges:	Concerns regarding data privacy and security High costs associated with data management and compliance

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Market Dynamics

Market Driver- Increasing integration of data analytics in healthcare

Integration of AI and machine learning in healthcare is advancing with the use of de-identified health data. This allows providers to share data freely for analytics, improving disease detection, drug discovery, and treatment recommendations. For instance, in October 2023, Microsoft, a technology company, launched new data and AI solutions, including Microsoft Fabric, a unified analytics platform that helps healthcare organizations securely access and analyze multimodal health data. This platform streamlines data integration, improving operational efficiency, accelerating clinical breakthroughs, and leveraging AI to enhance patient outcomes while reducing healthcare costs.

Market Challenge- Concerns regarding data privacy and security

Key challenge faced by De-identified Health Data Market includes risk of re-identification or exposure of sensitive patient data, thus, undermining public trust. While de-identified data is intended to protect privacy, inherent risks remain, especially with clinical and genomic data. Evolving legal and regulatory frameworks are addressing security and anonymization standards, but concerns over compliance and potential liabilities make organizations hesitant to share data widely. Ensuring strong privacy safeguards is crucial for the industry's growth and long-term viability.

Market Opportunity- Expansion of de-identified data applications in emerging markets

Expansion of de-identified data applications in emerging markets offers significant opportunities. As regions like Asia, Latin America, the Middle East, and Africa invest in digital health and electronic records, de-identified data sharing can support clinical research, improve public health outcomes, and reduce healthcare costs. With strong privacy protections, emerging markets could drive innovation in health data, unlocking commercial potential for data holders, life science firms, and healthcare analytics companies.

Key Stakeholders of Market

What growth in De-identified Health Data Market mean for Different Stakeholders?

De-identified health data market has multiple players with varied designations and offers multiple opportunities based on their scope of operations.

Key Healthcare IT Stakeholder	Opportunities Due to De-identified Health Data Industry Growth
Software Developers	Increased demand for developing healthcare applications, EHR systems, telemedicine platforms, and AI-driven diagnostics tools.
Healthcare Providers	Opportunities to implement and optimize EHR systems, telemedicine solutions, and patient portals, enhancing patient care and operational efficiency.
Healthcare IT Consultants	Providing expertise in the implementation and optimization of healthcare IT systems, compliance with health regulations, and digital transformation.
Data Analytics Firms	Growth in demand for advanced analytics solutions, including predictive analytics, population health management, and personalized medicine.
Cybersecurity Firms	Rising need for robust security solutions to protect sensitive health data, ensuring compliance with regulations like HIPAA and GDPR.
Hospital Administrators	Implementing and managing health IT infrastructure to streamline operations, reduce costs, and improve patient outcomes.
Medical Device Companies	Collaborating with healthcare IT firms to integrate devices with EHR systems, telemedicine platforms, and health monitoring applications.
Telemedicine Providers	Expansion of telemedicine services, enabling remote consultations, monitoring, and patient management, especially in underserved areas.

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Market Segmentation

Type of Data Insights (Revenue, USD Bn, 2019 - 2031)
- Clinical Data
- Genomic Data
- Patient Demographics
- Prescription Data
- Claims Data
- Behavioral Data
- Wearable and Sensor Data
- Survey and Patient-Reported Data
- Imaging Data
- Laboratory Data
- Social Determinants of Health (SDOH) Data
- Others
Application Insights (Revenue, USD Bn, 2019 - 2031)
- Clinical Research and Trials
- Public Health
- Precision Medicine
- Health Economics and Outcomes Research (HEOR)
- Population Health Management
- Drug Discovery and Development
- Healthcare Quality Improvement
- Insurance Underwriting and Risk Assessment
- Others
End User Insights (Revenue, USD Bn, 2019 - 2031)
- Pharmaceutical Companies
- Biotechnology Firms
- Healthcare Providers
- Insurance Companies/Healthcare Payers
- Research Institutions
- Government Agencies
- Others
Regional Insights (Revenue, USD Bn, 2019 - 2031)
- North America
  - U.S.
  - Canada
- Latin America
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
- Europe
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
- Asia Pacific
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
- Middle East
  - GCC Countries
  - Israel
  - Rest of Middle East
- Africa
  - South Africa
  - North Africa
  - Central Africa
Key Players Insights
- IQVIA
- Oracle (Cerner Corporation)
- Merative (Truven Health Analytics)
- Optum, Inc.
- BioTelemetry, Inc.
- Flatiron Health
- Veradigm LLC
- Medidata Solutions
- Evidation Health, Inc.
- Komodo Health, Inc.
- Sundown Solutions, LLC
- Clarify Health Solutions
- Akrivia Health
- Satori Cyber Ltd.
- Tempus
- nference
- Ciox Health
- HealthVerity
- Zebra Medical Vision
- Huma Therapeutics

About Author

Manisha Vibhute is a consultant with over 5 years of experience in market research and consulting. With a strong understanding of market dynamics, Manisha assists clients in developing effective market access strategies. She helps medical device companies navigate pricing, reimbursement, and regulatory pathways to ensure successful product launches.

Missing comfort of reading report in your local language? Find your preferred language :

Transform your Strategy with Exclusive Trending Reports :

Attention Bias Modification Treatment Ap...

Computerized Physician Order Entry Syste...

Telemonitoring System Market

Virtual Rehabilitation And Telerehabilit...

Patient Portal Software Market

U.S. Computer-Aided Detection (CAD) Mark...

Frequently Asked Questions

De-identified health data market is estimated to be valued at USD 7.51 Bn in 2024 and is expected to reach US$ USD 13.80 Bn by 2031.

The CAGR of de-identified health data market is projected to be 9.1% from 2024 to 2031.

Increasing integration of data analytics in healthcare and growing regulatory frameworks supporting the use of de-identified data are the major factors driving the growth of de-identified health data market.

Concerns regarding data privacy and security and high costs associated with data management and compliance are the major factors hampering the growth of the de-identified health data market.

In terms of type of data, clinical data segment is estimated to dominate the market in 2024.

IQVIA, Oracle (Cerner Corporation), Merative (Truven Health Analytics), Optum, Inc., BioTelemetry, Inc., Flatiron Health, Veradigm LLC, Medidata Solutions, Evidation Health, Inc., Komodo Health, Inc., Sundown Solutions, LLC, Clarify Health Solutions, Akrivia Health, Satori Cyber Ltd., Tempus, nference, Ciox Health, HealthVerity, Zebra Medical Vision, and Huma Therapeutics are the major players.

North America is expected to lead the de-identified health data market in 2024.